Amlodipine Besylate/Olmesartan Medoxomil/Rosuvastatin Calcium

苯磺酸氨氯地平/奥美沙坦酯/瑞舒伐他汀钙

Report date: 2022/03/08 16:45:38

Base Information

Drug NameAmlodipine Besylate/Olmesartan Medoxomil/Rosuvastatin Calcium
Drug Alias Name奥美沙坦酯/瑞舒伐他汀钙/苯磺酸氨氯地平/瑞舒伐他汀钙Olmersartan medoxomil/amlodipine besylate/rosuvastatin calciumOlmersartan medoxomil/amlodipine besilate/rosuvastatin calciumAmlodipine besylate/olmersartan medoxomil/rosuvastatin calciumAmlodipine/olmesartan/rosuvastatin +[8] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockersHMG-CoA reductase inhibitors
TargetsHMG-CoA reductaseAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsHyperlipidemiasDyslipidemiasHypertension
Global Approved IndicationsDyslipidemiasHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2019/01/27
Country/TerritorySouth Korea
CombinationsYes Amlodipine BesylateOlmesartan MedoxomilRosuvastatin Calcium
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDaewoong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaewoong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDyslipidemiasHypertension
Inactive IndicationsHyperlipidemias

Other Information

ATC CodeC09D
Related LinksN/A